# A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm

> **NCT05048160** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 272 (estimated)

## Conditions studied

- Advanced Malignant Neoplasm

## Interventions

- **DRUG:** Intravenous Infusion

## Key facts

- **NCT ID:** NCT05048160
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-27
- **Primary completion:** 2024-06
- **Final completion:** 2024-12
- **Target enrollment:** 272 (ESTIMATED)
- **Last updated:** 2022-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05048160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05048160, "A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05048160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*